<DOC>
	<DOC>NCT00113776</DOC>
	<brief_summary>The purpose of this study is to examine the safety of ABX-EGF administered as monotherapy in subjects with metastatic colorectal cancer who were previously randomized to best supportive care (BSC) in protocol 20020408 and subsequently determined to have progressive disease.</brief_summary>
	<brief_title>Evaluating ABX-EGF Extended Therapy in Subjects With MetastaticColorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Subject previously randomized to BSC in protocol 20020408 and subsequently determined to have progressive disease ECOG performance status of 0, 1 or 2 Adequate hematologic, renal and hepatic function Myocardial infarction in time interval between completing 20020408 and enrollment in study History or evidence of interstitial pneumonitis or pulmonary fibrosis Prior antitumor therapies including prior experimental agents or approved antitumor small molecules and biologics during the time interval between completing 20020408 protocol and enrollment in this study Use of systemic chemotherapy or radiotherapy during the time interval between completing 20020408 protocol and enrollment in this study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Metastatic Colorectal Cancer, Colon</keyword>
	<keyword>Colorectal, Rectal Cancer, EGFr</keyword>
	<keyword>Metastatic, Cancer, ABX-EGF</keyword>
	<keyword>Panitumumab, Clinical Trial</keyword>
	<keyword>Immunex, Abgenix, Amgen</keyword>
</DOC>